RxDoctor Payments Data

Leslie Neuberger

Psychiatric/Mental Health · Canton, OHNPI 1902541956

Payments from drug & device makers

$4,748in general payments, 2019–2025

Across 194 payments — averaging $24.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$839
  • AbbVie$714
  • Alkermes, Inc.$510
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$443
  • Johnson & Johnson$442
  • Axsome Therapeutics, Inc.$386
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,69999%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,748 in reported general payments places this provider in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$3,081
Medicare patients
21
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate45$357,536
Invega SustennaPaliperidone Palmitate21$67,235
VraylarCariprazine Hcl44$63,018
RexultiBrexpiprazole15$21,864
FanaptIloperidone18$11,364
Aripiprazole113$7,538
Paliperidone ErPaliperidone25$7,204
Ziprasidone Hcl50$5,221
Olanzapine58$4,229
Doxepin Hcl58$2,514
Hydroxyzine Hcl141$2,436
Oxcarbazepine44$2,039
Bupropion XlBupropion Hcl132$2,024
Divalproex Sodium17$1,980
Quetiapine Fumarate ErQuetiapine Fumarate30$1,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$313$357,53645 claims
Johnson & JohnsonInvega Sustenna$442$67,23521 claims
AbbVieVraylar$714$63,01844 claims
Otsuka America Pharmaceutical, Inc.Rexulti$250$21,86415 claims
Vanda Pharmaceuticals Inc.Fanapt$177$11,36418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →